ArticleJACC. Asia2026
Oncologic Benefits and Cardiovascular Risks of Pembrolizumab: Insights From a Nationwide Lung Adenocarcinoma Cohort.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab improves survival in advanced lung adenocarcinoma, but potential cardiovascular toxicity remains.
objectivesThis study evaluated the oncologic benefits and cardiovascular risks of pembrolizumab in a nationwide lung adenocarcinoma cohort.
methodsWe analyzed 39,192 patients newly diagnosed with lung adenocarcinoma between 2012 and 2019 using the nationwide cancer registry. We compared 573 patients treated with pembrolizumab within 1 year of diagnosis with 38,619 patients who were not treated within 3 years. The outcomes included all-cause mortality and myocardial infarction (MI), ischemic stroke (IS), heart failure (HF), pericarditis/myocarditis, and atrial fibrillation (AF) over a 3-year follow-up.
resultsDuring a median follow-up of 3.0 years (IQR: 1.0-3.0 years), 18,241 deaths, 574 MI, 1,157 IS, 2,777 HF, 852 pericarditis/myocarditis, and 1,601 AF events occurred. Model-based adjusted outcome curves showed lower all-cause mortality among users (adjusted P < 0.001) but higher incidences of IS, HF, and AF (adjusted P = 0.028, <0.001, and 0.048, respectively). Nonsignificant trends toward increased risks of MI and pericarditis/myocarditis were observed. Multivariable survival analyses, including Fine-Gray competing risk models for nonfatal cardiovascular outcomes, showed that pembrolizumab use was associated with lower all-cause mortality (HR: 0.77; 95% CI: 0.69-0.86) but with increased risks of IS (HR: 1.56, 95% CI: 1.10-2.23), HF (HR: 2.72, 95% CI: 2.24-3.30), and AF (HR: 1.47, 95% CI: 1.08-2.01); increases in MI and pericarditis/myocarditis were nonsignificant.
conclusionsPembrolizumab was associated with lower all-cause mortality but higher risks of major cardiovascular events. These findings support vigilant cardio-oncologic monitoring in patients treated with pembrolizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.